Dépôt numérique

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer

Rose, April A N; Grosset, Andrée-Anne; Dong, Zhifeng; Russo, Caterina; Macdonald, Patricia A; Bertos, Nicholas R; St-Pierre, Yves ORCID logoORCID: https://orcid.org/0000-0002-1948-2041; Simantov, Ronit; Hallett, Michael; Park, Morag; Gaboury, Louis et Siegel, Peter M (2010). Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer Clinical Cancer Research , vol. 16 , nº 7. pp. 2147-2156. DOI: 10.1158/1078-0432.CCR-09-1611.

Ce document n'est pas hébergé sur EspaceINRS.


PURPOSE: Although the murine orthologue of glycoprotein nonmetastatic B (GPNMB), Osteoactivin, promotes breast cancer metastasis in an in vivo mouse model, its importance in human breast cancer is unknown. We have examined the significance of GPNMB expression as a prognostic indicator of recurrence and assessed its potential as a novel therapeutic target in breast cancer.

EXPERIMENTAL DESIGN: The clinical significance of GPNMB expression in breast cancer was addressed by analyzing GPNMB levels in several published gene expression data sets and two independent tissue microarrays derived from human breast tumors. GPNMB-expressing human breast cancer cell lines were further used to validate a toxin-conjugated anti-GPNMB antibody as a novel therapeutic agent.

RESULTS: GPNMB expression correlates with shorter recurrence times and reduced overall survival of breast cancer patients. Epithelial-specific GPNMB staining is an independent prognostic indicator for breast cancer recurrence. GPNMB is highly expressed in basal and triple-negative breast cancers and is associated with increased risk of recurrence within this subtype. GPNMB expression confers a more migratory and invasive phenotype on breast cancer cells and sensitizes them to killing by CDX-011 (glembatumumab vedotin), a GPNMB-targeted antibody-drug conjugate.

CONCLUSIONS: GPNMB expression is associated with the basal/triple-negative subtype and is a prognostic marker of poor outcome in patients with breast cancer. CDX-011 (glembatumumab vedotin) is a promising new targeted therapy for patients with metastatic triple-negative breast cancers, a patient population that currently lacks targeted-therapy options.

Type de document: Article
Mots-clés libres: -
Centre: Centre INRS-Institut Armand Frappier
Date de dépôt: 09 juill. 2024 14:59
Dernière modification: 09 juill. 2024 14:59
URI: https://espace.inrs.ca/id/eprint/15120

Gestion Actions (Identification requise)

Modifier la notice Modifier la notice